Literature DB >> 16712668

Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.

Hugo João Prazeres1, Fernando Rodrigues, Paulo Figueiredo, Plamen Naidenov, Paula Soares, Maria João Bugalho, Manuela Lacerda, Beatriz Campos, Teresa C Martins.   

Abstract

OBJECTIVE: Medullary thyroid carcinoma (MTC) occurs both sporadically and in the context of autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN2) syndromes: MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC), which are caused by activating germline mutations in the RET proto-oncogene. The aim of this study was to characterize the RET mutational spectrum in MEN2 families and apparently sporadic MTC (AS-MTC) cases originating from the central region of Portugal. SUBJECTS AND METHODS: We studied a total of 82 individuals (64 affected and 18 family members), comprising five MEN2 families (four MEN2A and one MEN2B), as well as 53 AS-MTC cases. RET germline mutations were screened using PCR-DNA sequencing, SSCP and RFLP. The haplotypes associated with recurrent mutations were determined by fragment analysis of microsatellite markers, and by RFLP, in the case of intragenic polymorphisms.
RESULTS: Frequency of the Cys611Tyr (TGC-TAC) mutation was significantly increased in this region of Portugal, due to the fact that three apparently unrelated MEN2A/FMTC families, out of the five in which mutations were identified, harboured this specific mutation. Haplotype analysis revealed that a common haplotype was shared between two of these three families. We have also characterized a novel RET mutation, Arg886Trp, located in the tyrosine kinase domain, which was found in an AS-MTC case.
CONCLUSIONS: There are regional specificities in the relative frequency of RET mutations, which are consistent with a cluster-like distribution of specific disease-causing mutations, as a result of the inheritance of a shared haplotype. These data, along with the finding of a novel RET mutation (Arg886Trp), have important implications towards facilitating and improving the molecular diagnosis of hereditary MTC on a regional basis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16712668     DOI: 10.1111/j.1365-2265.2006.02524.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Rapid diagnosis of MEN2B using unlabeled probe melting analysis and the LightCycler 480 instrument.

Authors:  Rebecca L Margraf; Rong Mao; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

2.  Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.

Authors:  Taccaliti A; Silvetti F; Palmonella G; Boscaro M
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

3.  Different RET gene mutation-induced multiple endocrine neoplasia type 2A in 3 Chinese families.

Authors:  Qiuli Liu; Dali Tong; Wenqiang Yuan; Gaolei Liu; Gang Yuan; Weihua Lan; Dianzheng Zhang; Jun Zhang; Zaoming Huang; Yao Zhang; Jun Jiang
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

4.  Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.

Authors:  Jes Sloth Mathiesen; Jens Peter Kroustrup; Peter Vestergaard; Kirstine Stochholm; Per Løgstrup Poulsen; Åse Krogh Rasmussen; Ulla Feldt-Rasmussen; Mette Gaustadnes; Torben Falck Ørntoft; Thomas van Overeem Hansen; Finn Cilius Nielsen; Kim Brixen; Christian Godballe; Anja Lisbeth Frederiksen
Journal:  Thyroid       Date:  2017-01-13       Impact factor: 6.568

Review 5.  Multiple endocrine neoplasia 2: an overview.

Authors:  B Saravana-Bawan; J D Pasternak
Journal:  Ther Adv Chronic Dis       Date:  2022-02-25       Impact factor: 5.091

6.  Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.

Authors:  P Fanis; N Skordis; S Frangos; G Christopoulos; E Spanou-Aristidou; E Andreou; P Manoli; M Mavrommatis; S Nicolaou; M Kleanthous; M A Cariolou; V Christophidou-Anastasiadou; G A Tanteles; L A Phylactou; V Neocleous
Journal:  J Endocrinol Invest       Date:  2018-02-02       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.